SCIENTIFIC PUBLICATIONS
Recent Publications
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models. Agrawal N, Ates LS, Schille SA, Chaturvedi A, Vogt J, Vukovic N, Dulberger CL, Vogel AB, Diekmann J, Diken M, Şahin U. Nat Immunol. 2026 Aug;27(8):1653-1665. doi: 10.1038/s41590-026-02545-z. Epub 2026 Jun 12.
- Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts. Branchett WJ, Kim JW, Shields J, Chakravarty P, Lee J, Novsarka I, Slawinski H, Wilkinson KA, Wilkinson RJ, Kamil A, Verma R, Haldar P, O’Garra A. Nat Immunol. 2026 Aug;27(8):1577-1589. doi: 10.1038/s41590-026-02544-0. Epub 2026 Jun 24.
- Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance. Liao R, Luo M, Yang F, Xu L, Zhang J, Zhang W, Guan S, Zhang Y, Luo P, Cheng P, Yang J, Li Y, Wang Q. Drug Dev Res. 2026 Aug;87(5):e70335. doi: 10.1002/ddr.70335.
- A novel multiepitope peptide vaccine with intrinsic adjuvant confers protective immunity in mice against tuberculosis. Sharma M, Kumar D, Bedi AK, Yadav P, Bhatt P, Kathait S, Basil MV, Rani M, Kulshrestha R, Verma AK, Sharma M, Sharma S. Microb Pathog. 2026 Aug;217:108589. doi: 10.1016/j.micpath.2026.108589. Epub 2026 May 24.
- Reevaluation of mycobacterial phosphatidyl-myo-inositol mannosides (PIMs) as Toll-like receptor 2 (TLR2) agonists. Belkai S, Carrat C, Layre E, Cala-De Paepe D, Vercellone A, Blanc L, Dessaux C, Chanchabi C, Stella A, Burlet-Schiltz O, Canaan S, Vergne I, Nigou J, Gilleron M. J Lipid Res. 2026 Aug;67(8):101098. doi: 10.1016/j.jlr.2026.101098. Epub 2026 Jul 6.
- Investigating the role of baseline gut Akkermansia muciniphila and its co-metabolite palmitoleic acid in BCG vaccine efficacy: a preclinical study. Chen D, Chen L, Chen C, Yan Y, Wu X, Chen D, Yuan P, Long X, Zou Y, Lin J, Xu JF, Pi J, Zeng G, Lu Y, Ge Z. EBioMedicine. 2026 Aug;130:106404. doi: 10.1016/j.ebiom.2026.106404. Epub 2026 Jul 23.
- Optimized Mass Spectrometry to Uncover tuberculosis Biomarkers in Extracellular Vesicles From Asymptomatic Tuberculosis Patients. Nieto Ramirez LM, Shelton K, Belisle JT, Diaz G, Tameris M, Naidoo K, Churchyard G, Scriba T, Walzl G, Sterling TR, Hadley K, Mulenga H, Hatherill M, Dobos KM. J Infect Dis. 2026 Aug 3;234(1):e160-e169. doi: 10.1093/infdis/jiag086.
- Vγ9Vδ2 T cells in tuberculosis: protective immunity and translational perspectives. Shi Z, Ding Y, Jing X, Wang F, Huang X, Wang P, Liu H, Niu N. Front Immunol. 2026 Aug 3;17:1884056. doi: 10.3389/fimmu.2026.1884056.
- Construction of a subunit vaccine based on Mycobacterium tuberculosis EsxE and evaluation of its immunogenicity and ex vivo mycobacterial growth inhibitory activity. Wang R, Wang X, Wang B, Xu Y, Zhong Q, Zhou M, Wang S, Xiao R, Yang G. Arch Microbiol. 2026 Aug 7;208(11):546. doi: 10.1007/s00203-026-05076-1.
- Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes. Shamskhou EA, Duffy FJ, Cross LM, Plumlee CR, Gern BH, Barrett HW, Diercks AH, Cohen SB, Sivakumar R, Aitchison JD, Ganusov VV, Urdahl KB, Gerner MY. Immunity. 2026 Aug 11;59(8):2122-2141.e9. doi: 10.1016/j.immuni.2026.05.017. Epub 2026 Jun 23.
- BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice. Tsai CY, Xie M, Cristaldo M, Peluso GR, Woo J, Nuritdinov F, Odjourian NM, Dougher M, Antilus-Sainte R, Kreutzfeldt KM, Ehrt S, Gengenbacher M. J Infect Dis. 2026 Aug 12:jiag416. doi: 10.1093/infdis/jiag416. Epub ahead of print.
- BCG overexpressing Ag85B reprograms host immune response through coordinated transcriptional networks. Chauhan V, Kumar R, Veerapandian R, Ramos EI, Jagannath C, Gadad SS, Dhandayuthapani S. Front Immunol. 2026 Aug 12;17:1876830. doi: 10.3389/fimmu.2026.1876830.
- The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design. Dagnew AF, Schmidt AC, Cinar A, Garcia-Basteiro AL, Noble R, Pelzer PT, Churchyard GJ, Hatherill M, White RG, Cobelens F. Vaccine. 2026 Aug 13;88:128822. doi: 10.1016/j.vaccine.2026.128822. Epub 2026 Jun 10.
- In silico comparison of the differential proteome produced by the tuberculosis vaccine candidate BCGΔBCG1419c and its parental BCG strain cultured as biofilms or planktonic cells. Flores-Valdez MA, Velázquez-Fernández JB, Vallejo-Cardona AA, Aceves-Sánchez MJ, Rodríguez-Campos J. Vaccine. 2026 Aug 13;88:128855. doi: 10.1016/j.vaccine.2026.128855. Epub 2026 Jun 19.
- Booster vaccine reduces BCG-primed mice’s protection against primary Mycobacterium tuberculosis infection by raising IL-10 levels. Lei Q, Lin X, Yao Z, Fu H, Wang Y, Yuan Y, Ouyang Q, Xu X, Cao J, Gan M, Fan X. Vaccine. 2026 Aug 13;88:128841. doi: 10.1016/j.vaccine.2026.128841. Epub 2026 Jun 17.
- Conference report: airway mucosal sampling and immune analysis. Rosenheim J, Bender B, Gilmour J, Jambo K, Jensen JUS, King D, Kløverpris H, Taylor S, Boaz M, Chiu C, Crotty S, Dahlke C, Dheda K, Fortune S, Higham SL, Holm M, Jochems SP, Krammer F, Lindestam Arlehamn CS, Mankouri HW, Marquart HV, McShane H, Mortensen R, Nemes E, Ordovas-Montanes J, Roberts PC, Ruhwald M, Schully KL, Thålin C, Thwaites RS, Wang TY, Juel HB. 2026 Aug 13;88:128944. doi: 10.1016/j.vaccine.2026.128944. Epub 2026 Jul 17.
- Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi. Chirwa AE, Gunda C, Songolo S, Nsomba E, Toto N, Makhaza L, Mailboy M, Ngoliwa C, Chamtunga L, Reuben M, Chakwiya C, Liwonde P, Sigoloti A, Kudowa E, Tembo G, Morton B, Galafa B, Thole F, Chimgoneko L, Dzonzi B, Nkhoma V, Mangani E, Mayuni M, Muyaya A, Kapakasa F, Kamanga MP, Nthandira T, Mwaipaya D, Chirwa N, Banda NPK, Henrion MYR, Chikaonda T, Jambo KC, Kapumba B, Gordon SB, Gordon ACT, Nyirenda D; Malawi Accelerated Research in Vaccines by Experimental and Laboratory Systems (MARVELS) consortium. PLOS Glob Public Health. 2026 Aug 18;6(8):e0006236. doi: 10.1371/journal.pgph.0006236.
- Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial. Nduba V, Mathebula M, Nankabirwa V, Dempster M, Mhimbira F, Sabi I, Wajja A, Cotton MF, Barnabas S, Adegnika AA, Kaufmann SHE, Brückner S, May M, Höß CW, Revathy M, Niranjan V, Bhargava A, Gupta M, Kapse D, Desai S, Grode L, Kulkarni PS, Shaligram U; priMe consortium. Lancet Infect Dis. 2026 Aug 18:S1473-3099(26)00374-9. doi: 10.1016/S1473-3099(26)00374-9. Epub ahead of print.
- Lessons from another negative tuberculosis vaccine trial. McShane H. Lancet Infect Dis. 2026 Aug 18:S1473-3099(26)00412-3. doi: 10.1016/S1473-3099(26)00412-3. Epub ahead of print.
- Toxicological evaluation of a synthetic QS-21 adjuvant in a tuberculosis vaccine candidate-Demonstrating safety and immunological equivalence to natural reference. Ping H, Li Y, Ding Y, Qin L, Zou Y, Wang Y, Chen Q, Zhang Y, Zhou C, Yi Q, Liu Y. Hum Vaccin Immunother. 2026 Dec;22(1):2713901. doi: 10.1080/21645515.2026.2713901. Epub 2026 Aug 19. PMID: 42617655; PMCID: PMC13502021.
- A renewed role for DNA vaccines for tuberculosis. Counoupas C, Britton WJ. Mol Ther. 2026 Aug 20:S1525-0016(26)00681-7. doi: 10.1016/j.ymthe.2026.07.058. Epub ahead of print.
- Opportunities and challenges for mRNA vaccines against tuberculosis. Chan EH, Lukeman HJ, Counoupas C, Triccas JA.npj Vaccines 2026 Aug 21. https://doi.org/10.1038/s41541-026-01566-x
- Antigen-experienced airway CD8+effector memory T cells promote a detour pathway for mycobacterial killing in the spleen. Seifert J, Muruganandah V, Miranda-Hernandez S, Sathkumara HD, Valencia-Hernandez AM, Pai S, Kupz A. Sci Adv. 2026 Aug 21;12(34):eaec7792. doi: 10.1126/sciadv.aec7792. Epub 2026 Aug 21.
- Styrene Maleic Acid Lipid Particles Prepared from Mycobacterium tuberculosis Plasma Membrane can Potentially Induce Innate and Adaptive Immune Responses in Healthy Individuals of a Tuberculosis Hyperendemic Region. Sinha S, Athar S, Agrawal V, Aggarwal A, Kumar A. Curr Microbiol. 2026 Aug 26;83(10):544. doi: 10.1007/s00284-026-05097-5. PMID: 42645576.
- In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach. Liaqat A, Dastgir K, Sajjad M, Rehman HM, Akhtar MW. PLoS One. 2026 Aug 27;21(8):e0356788. doi: 10.1371/journal.pone.0356788.
- Genetic characterization of tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine. Wattiau P, Omar SV, Joseph L, Demoitié MA, Gilbert M, Ayles HM, Diacon AH, Ginsberg AM, Hatherill M, Hellström E, Innes JC, Malahleha M, Martinson N, Muyoyeta M, Nduba V, Tait DR, Wilkinson RJ, Roman F. J Infect Dis. 2026 Aug 28:jiag428. doi: 10.1093/infdis/jiag428. Epub ahead of print.
- An adenovirus-based multiantigen vaccine protects against tuberculosis by coordinating adaptive immunity and curbing immunosuppressive mechanisms. Wei L, Wang P, Li Y, Li X, Shen X, He F, Guo Y, Xing M, Zhou D. Microbiol Spectr. 2026 Aug 28:e0090726. doi: 10.1128/spectrum.00907-26. Epub ahead of print.
- Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates. Andrews JR, Hermans S, White RG, García-Basteiro AL, Croda J, Cobelens F. Vaccine. 2026 Aug 31;91:129097. doi: 10.1016/j.vaccine.2026.129097. Epub ahead of print.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D